Oliver Bogler

Please share this with as many people as possible – particularly men who are breast cancer survivors, as Dr. Henneghan has adjusted to the study to make men eligible! If you are eligible, You will schedule a time to complete a survey and do cognitive testing (about 30 minutes via video conference). 8 weeks after you start the daily program you will repeat the survey and cognitive testing (about 30 minutes via video conference). After the 16 weeks you will do a final survey, cognitive testing (about 30 minutes via video conference) and exit interview.

This study is evaluating how a meditation intervention improves cognitive functioning after breast cancer treatment. If you are eligible, you will schedule a time to complete a survey and do cognitive testing (about 30 minutes via video conference). 8 weeks after you start the daily program you will repeat the survey and cognitive testing (about 30 minutes via video conference). After the 16 weeks, you will do a final survey, cognitive testing (about 30 minutes via video conference) and exit interview.

I am doing very well and had the chance of a lifetime earlier this year to join the amazing team at the ECHO Institute to work on Project ECHO. Changing jobs, moving and all the exciting work we have been doing made it hard for me to keep up posts – although I have tried to remain active on Twitter for breast cancer trials. I will write more about my work at ECHO soon – time allowing – I am attending the Biden Cancer Summit tomorrow and am excited to be part of this new wave of energy in the ongoing fight against cancer!

This study leverages the work of the International Male Breast Cancer Program which is a European-American collaboration involving many centers, including MD Anderson Cancer Center, where I work and receive my cancer care. Analysis of the DCIS and aggressive tumors next to them for various characteristics, including hormone receptor (ER/PR) and Her2 status and for a handful of cases the presence of known mutations in female breast cancer (PIK3CA, GATA3, TP53 and MAP2K4) showed that these were almost always shared, which suggests the more advanced and aggressive components were derived from the DCIS lesions. The authors also looked at whether the presence of DCIS adjacent to the invasive tumor was associated with differential survival, and found this to be true for Luminal B Her2+ subgroup, which is a relatively small minority of male breast cancers. This study provides solid evidence that invasive male breast cancers derive from DCIS lesions, as is the case for female breast cancers that are like them, i.e. invasive ductal carcinomas.